A Phase 2, Single-Blind, Exploratory, Placebo-controlled, Pilot Study to Assess the Efficacy and Safety of Daily Oral NYX-2925 in Subjects With Fibromyalgia
Phase of Trial: Phase II
Latest Information Update: 03 Dec 2018
At a glance
- Drugs NYX 2925 (Primary)
- Indications Fibromyalgia
- Focus Biomarker; Pharmacodynamics
- Sponsors Aptinyx
- 03 Dec 2018 According to an Aptinyx media release, this study is ongoing with the full data expected to read out in the first half of 2019. Once completed, the company plans to submit the detailed results from this study for publication and presentation at future scientific and medical meetings.
- 03 Dec 2018 Interim analysis results (n=11) presented in an Aptinyx media release.
- 13 Nov 2018 According to an Aptinyx media release, the company expects to report data from interim analysis in December of 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History